Chris Chai and Peter Van Vlasselaer, both former executives at SR One portfolio companies, have been hired by the GSK-backed VC firm as venture partners.
SR One, the venture capital firm spun off by pharmaceutical firm GlaxoSmithKline (GSK), has recruited Chris Chai and Peter Van Vlasselaer as venture partners.
GSK spun off the unit into an independent firm in November 2020 with $500m in funding and operates out of offices in London in the UK, as well as San Francisco and Philadelphia in the United States.
Chai had been chief financial officer of Principia Biopharma, the biopharmaceutical company that floated in 2018 having raised…
